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Abstract 
Background: CD44 is well known to be one of the cancer stem cell markers and is a cell-surface 
glycoprotein involved in cell-cell interactions, cell adhesion, and cell migration. We investigated the 
role of CD44 expression in both tumor and non-tumor tissues on recurrence of hepatocellular 
carcinoma (HCC). 
Methods: Forty-eight patients with HCC who underwent hepatic resection at our institution were 
enrolled in this study. CD44 expressions in both tumor and non-tumor tissues were examined using 
real time reverse transcription-polymerase chain reaction. The patients were divided into two groups: 
high and low gene-expression group, based on the CD44 expression level. We compared the 
clinicopathological factors between the high expression and low expression groups in both tumor 
and non-tumor tissues. 
Results: In the tumor tissues, the gene-expression levels of CD44 did not correlate with any 
clinicopathological parameters. The disease-free survival rate showed no significant difference 
between the two gourps. In non-tumor tissues, although there was no significant relationship 
between the CD44 expression levels and clinicopathological factors, disease-free survival rate in the 
CD44 low expression group was significantly better than that in the CD44 high expression group 
(p<0.05). In multivariate analysis, the risk factors in tumor recurrence were presence of microscopic 
portal invasion and high expression level of CD44. 
Conclusion: The CD44 expressions in the non-tumor tissues may predict HCC recurrence. 
 
Mini abstract 
The CD44 expressions in the non-tumor tissues may be a significant prognostic factor in patients 
with hepatocellular carcinoma. 
 
Key words: hepatocellular carcinoma, CD44, prognostic factor, non-tumor tissue 
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Abbreviations 
HCC  hepatocellular carcinoma 
RT-PCR  reverse transcription-polymerase chain reaction 
GAPDH  glyceraldehydes-3-phosphate dehydrogenase 
AST  aspartate aminotransferase 
ALT  alanine transaminase 
WBC  white blood cell 
PT  prothrombin time 
ICGR15  indocyanine green retention rate at 15 minutes 
AFP  alpha-fetoprotein 
DCP  des-gamma-carboxy prothrombin 
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Introduction 
Hepatocellular carcinoma (HCC) is well known to be one of the most common malignancy 
and cause of cancer-related death. The HCC has poor prognosis, in advanced stages due to 
recurrence and distant metastasis [1, 2]. Some studies reported that the five-year survival rate of 
patients after curative resection of HCC were 30-50 percent [3]. Therefore, it is important to 
elucidate the prognostic factors and establish treatment strategy to overcome the poor prognosis of 
HCC. 
CD44 is one of the cancer stem cell markers, highly glycosylated transmembrane protein, 
widely expressed cell surface hyaluronan receptor, with composes of a distal extracellular domain, a 
membrane-proximal region, a transmembrane spanning domain, and a cytoplasmic tail [4-6]. CD44 
participates in a relatively diverse set of functions including lymphocyte homing, T-lymphocyte 
activation, signal transmission involved in cell proliferation, migration and apoptosis. CD44 also 
contribute to the activation of stem cell regulatory genes [5, 7, 8]. CD44 is essential to the 
physiological activities of normal cells, but it was also associated with pathologic activities of cancer 
cells [8]. 
Recently, a number of studies suggest that CD44 can involve for cancer stem cells. Jin L et al 
reported that CD44 is a key regulator function of leukemic stem cells in acute myeloid leukemia [9]. 
More recent studies have shown that stem cell-like properties are enriched in CD44-expressing 
subpopulations of some lung cancer cell lines and also reported that CD44 positive population may 
be the best to identify tumor initiating cells of human colon cancer [10, 11]. 
Compared with control counterparts, the enhanced expression of CD44 in malignant tissues 
can be detected in several cancers, such as breast cancer, colorectal cancer, renal cell carcinoma, 
HCC, gallbladder carcinoma, ovarian carcinoma [8-11]. Over expression of CD44 is also correlated 
with hallmarks of cancer biology including tumorigenesis, cell proliferation, and metastasis. CD44 is 
emerging as an important metastatic tumor marker and is also associated with an unfavorable 
prognosis for a variety of cancers, including HCC [6-8, 12-15]. 
However, the detailed pathological role of CD44 in HCC was unclear. The aim of this study 
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was, therefore, to investigate the expression of CD44 by real time reverse transcription-polymerase 
chain reaction (RT-PCR) in both tumor and non-tumor tissues, and to clarify its clinical significance. 
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Patients and methods 
Patients 
Forty-eight patients with HCC, who underwent hepatic resection at Tokushima University 
Hospital between 2005 and 2009, were included in this study. 
 
Quantitative RT-PCR for CD44 
The gene-expression levels of CD44 in the tumor and non-tumor liver tissues from the 48 
HCC patients were evaluated by quantitative RT-PCR. Total RNA was extracted from using RNeasy 
Mini Kit (QIAGEN, Hilden, Germany). Quantitative RT-PCR was performed by the Applied 
Biosystems 7500 real-time PCR
 
system, TaqMan Gene Expression Assays-on-demand, and TaqMan
 
Universal Master Mix (Applied Biosystems).
 
The following assays (assay identification number) 
were
 
used: CD44 (Hs01075865_m1). TaqMan Human GAPDH Endogenous Control (4326317E) 
was used as control gene. Expression levels of the CD44 were calculated as a ratio to GAPDH. The 
thermal cycler conditions were as follows: 2 min
 
at 50°C, 10 min at 95°C, then 40 cycles of 15 sec at 
95°C and
 
1 min at 60°C. Amplification data were analyzed with an Applied Biosystems Prism 7500 
Sequence Detection System version 1.3.1 (Applied Biosystems). 
 
Patients follow-up 
All patients were followed-up regularly in the outpatient clinic and monitored prospectively 
for recurrence by a standard protocol including serum AFP and des-gamma-carboxy prothrombin 
(DCP) level and ultrasound or contrast computed tomography (CT). Patients were followed up every 
2 months during the first postoperative year and at least every 3–4 months afterward. AFP 
examination and liver ultrasonography were performed during each visit. CT scan of the abdomen 
was performed every 6 months. Bone scan or magnetic resonance imaging (MRI) was performed if 
localized bone pain was reported. A diagnosis of recurrence was based on typical imaging 
appearance in CT and/or MRI and an elevated AFP and/or DCP level. 
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Statistical analysis 
All results were presented as a mean ± SD. For comparison of continuous variables, the 
Mann-Whitney U test was used, and the chi-squared test was applied for categorical data. Patient 
survival was calculated by the product limit method of Kaplan and Meier, and differences in survival 
rates between the groups were compared using the log rank test. Prognostic factors were examined 
using univariate and multivariate analyses (Cox proportional hazards regression model). The 
continuous variables were generally classified into two groups, according to the median value of 
each variable. All statistical analysis was performed using statistical software (JMP 8.0.1., SAS 
Campus Drive, Cary, NC). Statistical significance was defined as a P value less than 0.05. 
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Results  
The expression level of CD44 mRNA in HCC  
The patients were divided into two groups according to the median value of expression level 
in the tumor tissue: CD44 high expression group (n=25) and low expression group (n=23). There 
was no relationship between CD44 gene expression and clinicopathological factors. The expression 
level of CD44 mRNA did not correlate with any parameters, such as age, sex, HBsAg, HCVAb, 
tumor size, number and stage (Table 1). The disease-free survival rate showed no significant 
difference between the two gourps (Figure 1). 
In the non-tumor tissue analysis, the 48 patients were also divided into two groups according 
to the median value of CD44 expression level: low expression group (n=24) and high expression 
group (n=24). There was no significant relationship between the expression level of CD44 mRNA 
and clinicopathological factors (Table 2). Liver function test such as serum albumin level, 
prothrombin time and ICGR15 value didn’t correlated with CD44 mRNA expression level. Similarly 
there was no significant correlation between tumor factors and CD44 mRNA expression. However, 
the disease-free survival rate in the CD44 low expression group was significantly higher than that in 
the CD44 high expression group (1-year: 70.1% vs. 50.1%, 3-year: 40.9% vs. 18.2%, p<0.05) 
(Figure 2). 
Recurrence rate of CD44 high expression group was more frequent than that in the CD44 low 
expression group (70.8% vs. 41.7%), and most of the recurrent site was liver in both groups (Figure 
3). The incidence of extrahepatic recurrence was higher in the CD44 high expression group (4/17) 
than that in the low expression group (1/10). 
In the univariate analysis, Stage III or IV, microscopic portal invasion, intrahepatic metastasis, 
and CD44 high expression were determined as the significant risk factors of tumor recurrence. The 
multivariable analysis revealed presence of microscopic portal invasion and CD44 high expression 
were independent and significant risk factors of tumor recurrence (Table 3, 4). 
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Discussion 
In this study, we investigated the expression of CD44 using quantitative RT-PCR and tried to 
clarify its clinical role. Our results showed that there was no significant relationship between the 
gene-expression levels of CD44 and clinicopathological factors in both the tumor tissues and the 
non-tumor tissues. The disease-free survival rate showed no significant difference between high and 
low CD44 expression group in the tumor tissues. In the non-tumor tissues, however, the disease-free 
survival rate in the CD44 low expression group was significantly higher than that in the CD44 high 
expression group. This is the first report suggesting that the gene-expression level of cancer stem 
cell markers in non-tumor tissues may be associated with a risk of tumor recurrence. 
To clarify which cell types were responsible for the higher expression of CD44 in the 
non-tumor liver tissues, we investigated the CD44 expressions in the liver tissue specimens by 
immunohistochemical staining. However, we could not detect any CD44 expression in the 
non-tumor tissue (Figure 4). We speculated that there is no detectable CD44 expression at the protein 
level in each cell. We could detect CD44 expression in the non-tumor tissues by amplifying the 
expression at the mRNA level using RT-PCR. 
There are at least two possible mechanisms to explain why the frequency of intrahehatic 
recurrence in the patients with high CD44 expression was significantly higher than that in those with 
low CD44 expression in the non-tumor tissues. The first is the possible explanation from the 
viewpoint of field cancerization, while the second is given from the viewpoint of micrometastasis.  
Several studies have shown that the specific gene-expression patterns in cancerous tissues of 
HCC can accurately predict early recurrence, possibly due to the intrahepatic metastasis of HCC 
[16-18]. However, the outcomes of the patients with HCC even after a curative hepatectomy have 
been unsatisfied, at least partially, because of its multicentric origin [19, 20]. We have previously 
shown the importance to investigate the noncancerous portion of liver tissues to examine the 
molecular mechanisms during the process of liver carcinogenesis based on the idea of ‘‘field 
carcinogenesis’’ is necessary, because multicentric occurrence of HCC is mainly associated with 
underlying chronic liver damage rather than adverse tumor factors [21, 22]. The role of CD44 in 
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heopatocarcinogenesis remains unclear. However, Endo et al. have indicated that some isoforms of 
CD44 were positive in cirrhosis and chronic hepatitis, and these CD44 molecules might play roles in 
the early stage of HCC development [15]. Although a number of studies have shown that the tumor 
expression level of a cancer stem cell marker; CD44 is closely related to the tumor aggressiveness 
and poor prognosis, our findings suggest that the non-tumor expression level of CD44 may also be 
an important clinical indicator in terms of the hepatocarcinogenesis.  
Another possible mechanism is a role of CD44 during the steps of tumor metastasis. 
Fundamentally, CD44 has a crucial role in regulating solid tumor cell adhesion to the surrounding 
normal tissues [23]. In the steps of tumor metastasis, cancer cells invade the basement membrane 
and underlying collagen matrix, migrate into the vascular system, adhere to endothelium of the 
target organ, and multiply to create a tumor. Invasion through the basement membrane represents 
one of the first step in this process, and CD44 was considered to be involved in this process of tumor 
metastasis [24, 25]. These findings explain the mechanisms by which high CD44 expression levels 
in tumor cells may be associated with a high potential of tumor metastasis. On the other hand, the 
contribution of CD44 to remodeling of microenvironment through the activation of cathepsin and 
metalloproteinase 9 has also been reported [24]. Therefore, it is conceivable that migrating HCC 
cells into the vascular system may be prone to adhere to non-tumor liver tissue, which is expressing 
high levels of CD44. Our data show that the pattern of recurrence was mainly intrahepatic 
recurrence. Although we did not determine the expression levels of CD44 in other organs, non-tumor 
liver tissues underlying chronic liver disease might express highest levels of CD44 compared to 
other organs. 
In addition, a possible drawback of this study might be the relatively small number of patients 
examined. These findings and phenomenon should certainly be confirmed in larger number of 
patients with chronic liver disease and HCC. 
In conclusion, the patients with high expression levels of CD44 in non-tumor liver tissues had 
a significantly poorer disease-free survival rate, mainly due to the intrahepatic recurrence. Therefore, 
the assessment of CD44 expressions in the non-tumor tissues may help us to identify a group of 
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patients who have a high risk for development of intrahepatic recurrence after hepatic resection for 
HCC. 
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Figure legends 
Figure 1 
Disease-free survival in patients with low and high expression of CD44 in tumor tissue. 
There was no significant difference between the two groups. 
 
Figure 2 
Disease-free survival in patients with low and high expression of CD44 in non-tumor tissue. 
Disease free survival rate was significantly higher in CD44 low expression group than that in CD44 
high expression group.  
 
Figure 3 
Recurrence pattern between CD44 high and low group. 
Most of the recurrent site was liver in both groups. 
MC: multicentric recurrence 
 
Figure 4 
CD44 expressions in the tumor and the non-tumor tissue by immunohistochemical staining. 
CD44 expression in the non-tumor tissue was not observed. 
T: tumor, NT: non-tumor 
Table 1. Relationship between tumor tissue expressions of CD44 with 
clinicopathological variables 
 
ALT: alanine transaminase, PT: prothrombin time, ICGR15: indocyanine green 
Factor CD44 low (n=23) CD44 high (n=25) P value 
Age (year) 66.7 68.1 0.60 
Gender (M/F) 15/8 19/6 0.41 
HBs-Ag (+/-) 6/17 9/16 0.46 
HCV-Ab (+/-) 9/14 10/15 0.95 
Albumin (g/dl) 3.6±0.9 3.6±0.5 0.90 
T-Bil (mg/dl) 0.8±0.3 0.9±0.3 0.24 
ALT (IU/L) 41±28 41±25 0.98 
PT (sec) 11.2±2.6 12.0±0.8 0.13 
ICGR15 (%) 12.7±6.6 14.0±8.9 0.57 
Stage (I, II / III, IV) 15/8 11/14 0.14 
Maximum diameter (cm) 5.0±3.5 4.6±3.5 0.71 
Number (single/multiple) 16/7 19/7 0.75 
Background liver (LF, CH / LC) 15/8 17/8 0.92 
fc (+/-) 16/7 16/9 0.75 
vp (+/-) 6/17 8/17 0.55 
Differentiation (well / mod, por) 3/20 4/21 0/75 
AFP (>200ng/ml) 5/12 7/17 0.62 
DCP (>400mAU/ml) 12/10 9/13 0.36 
retention rate at 15 minutes, LF: liver fibrosis, CH: chronic hepatitis, LC: liver cirrhosis, 
AFP: alpha-fetoprotein, DCP: des-gamma-carboxy prothrombin 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Relationship between non-tumor tissue expressions of CD44 with 
clinicopathological variables 
 
ALT: alanine transaminase, PT: prothrombin time, ICGR15: indocyanine green 
Factor CD44 low (n=24) CD44 high (n=24) P value 
Age (year) 66.7 68.0 0.88 
Gender (M/F) 20/4 14/10 0.06 
HBs-Ag (+/-) 10/14 5/19 0.17 
HCV-Ab (+/-) 8/16 11/13 0.38 
Albumin (g/dl) 3.8±0.5 3.6±0.5 0.18 
T-Bil (mg/dl) 0.9±0.3 1.0±0.3 0.55 
ALT (IU/L) 42.7±28.2 43±27 0.76 
PT (sec) 11.8±1.0 11.8±0.9 0.97 
ICGR15 (%) 13.9±7.6 14.4±8.6 0.91 
Stage (I, II / III, IV) 16/8 10/14 0.08 
Maximum diameter (cm) 4.4±4.0 4.1±2.8 0.23 
Number (single/multiple) 19/5 16/8 0.26 
Background liver (LF, CH / LC) 17/7 14/10 0.26 
fc (+/-) 16/8 15/9 0.91 
vp (+/-) 7/17 7/17 0.53 
Differentiation (well / mod, por) 3/21 4/20 0.32 
AFP (>200ng/ml) 6/18 6/16 0.86 
DCP (>400mAU/ml) 8/15 13/8 0.07 
retention rate at 15 minutes, LF: liver fibrosis, CH: chronic hepatitis, LC: liver cirrhosis, 
AFP: alpha-fetoprotein, DCP: des-gamma-carboxy prothrombin 
Table 3. Risk factors in tumor recurrence: univariate analysis 
Variable  3 year survival (%) p Value 
Host factors at recurrence 
 Gender 
male 
female 
 
 
(n=34) 
(n=14) 
 
 
34.9 
20.3 
 
 
0.5857 
Age 
  ≤70 
  >70 
 
(n=23) 
(n=25) 
 
41.6 
19.5 
 
0.7711 
Diabetes 
absent 
present 
 
(n=30) 
(n=18) 
 
29.5 
36.0 
 
0.2901 
Hypertension 
absent 
present 
 
(n=24) 
(n=24) 
 
12.4 
44.3 
 
0.1606 
HBsAg 
  negative 
  positive 
 
(n=33) 
(n=15) 
 
21.9 
47.9 
 
0.6620 
HCV 
  negative 
  positive 
 
(n=29) 
(n=19) 
 
49.7 
9.9 
 
0.1083 
Child`s class 
  A 
  B 
 
(n=45) 
(n=3) 
 
33.0 
0 
 
0.4584 
PT 
  ≤12 sec 
  >12 sec 
 
(n=29) 
(n=19) 
 
72.3 
35.5 
 
0.8053 
TBil 
≤1.0 mg/dL 
>1.0 mg/dL 
 
(n=34) 
(n=14) 
 
37.4 
13.4 
 
0.0633 
Albumin 
≥3.5 g/dL 
  <3.5 g/dL 
 
(n=35) 
(n=13) 
 
33.0 
23.4 
 
0.5973 
ALT 
≤40 IU/dL 
>40 IU/dL 
 
(n=31) 
(n=17) 
 
28.7 
36.8 
 
0.4434 
ICG R15 
≤10% 
>10% 
 
(n=18) 
(n=30) 
 
22.4 
37.9 
 
0.7765 
Background liver 
LF, CH 
LC 
 
(n=32) 
(n=16) 
 
33.6 
35.6 
 
0.5349 
Stage  
I, II 
III, IV 
 
(n=26) 
(n=22) 
 
50.2 
15.0 
 
0.0275 
AFP 
≤200 ng/ml 
>200 ng/ml 
 
(n=34) 
(n=12) 
 
34.0 
0 
 
0.0723 
DCP 
≤400 mAU/ml 
>400 mAU/ml 
 
(n=23) 
(n=21) 
 
32.9 
24.2 
 
0.5608 
Tumor factors 
Tumor number 
  single nodule 
  multiple nodules 
 
 
(n=34) 
(n=11) 
 
 
40.4 
20.0 
 
 
0.4635 
Tumor size 
  ≤3 cm 
  >3 cm 
 
(n=23) 
(n=23) 
 
40.4 
26.7 
 
0.3709 
Histology 
  Well 
  Mod, por 
 
(n=6) 
(n=38) 
 
33.3 
40.0 
 
0.3966 
Fc 
  absent 
  present 
 
(n=15) 
(n=31) 
 
44.0 
32.0 
 
0.6814 
vp 
  absent 
  present 
 
(n=33) 
(n=12) 
 
44.0 
19.0 
 
0.0093 
Im 
  absent 
  present 
 
(n=37) 
(n=9) 
 
49.6 
0 
 
0.0012 
CD 44 
high 
  low 
 
(n=24) 
(n=24) 
 
18.2 
50.1 
 
0.0337 
 
PT: prothrombin time, ALT: alanine transaminase, ICGR15: indocyanine green retention 
rate at 15 minutes, LF: liver fibrosis, CH: chronic hepatitis, LC: liver cirrhosis, AFP: 
alpha-fetoprotein, DCP: des-gamma-carboxy prothrombin 
Table 4. Risk factors in tumor recurrence: multivariate analysis 
 
 
 
 
 
 
 
 
 
 
 
H.R – Hazard Ratio  C.I - Confidence interval 
 Multivariate 
 H.R.  95% C.I.  p-value  
vp (+) 2.907 0.119-1.000 0.0499 
im (+) 1.996 0.160-1.570 0.2352 
Stage III, IV 
 
1.002 0.338-2.946 0.9965 
CD44: high 
 
 
 
 
2.963 
 
1.111-7.907 0.0300 
0 
20 
40 
60 
80 
100 
3 2 1 0 4 
Figure 1 
          CD44 low (n=23) 
          CD44 high (n=25) 
Disease-free survival 
(%) 
S
u
rv
iv
a
l 
ra
te
 
Years after operation 
- Tumor tissue - 
p=0.85 
0 
20 
40 
60 
80 
100 
3 2 1 0 4 
Figure 2 
          CD44 low (n=24) 
          CD44 high (n=24) 
Disease-free survival 
(%) 
S
u
rv
iv
a
l 
ra
te
 
Years after operation 
- Non-tumor tissue - 
p<0.05 
CD44 high CD44 low 
n=24 
Yes 
(n=17) 
No  
(n=7) 
n=24 
Yes  
(n=10) 
No  
(n=14) 
n=17 n=10 
Liver 
(n=13)  
Lung (n=1) 
Liver  
(n=9) 
Liver + Lung  
(n=2) 
Liver + LN  
(n=1) 
Liver + Bone  
(n=1) 
Liver: 16/17 
(MC: 6) 
Liver: 10/10 
(MC: 3) 
Figure 3 
x200 
x40 
NT 
T 
Figure 4 
